Search

Search Constraints

You searched for: Author/Creator Fazal, S.

Search Results

2. P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX). (23rd June 2022)

3. Topic: AS08-Treatment/AS08a-Current treatment options - Hypomethylating agents: PROLONGED SURVIVAL OBSERVED IN 133 MDS PATIENTS TREATED WITH ORAL DECITABINE/CEDAZURIDINE. (September 2021)

4. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES. (May 2023)